Vident Advisory’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Vident Advisory’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-39,864	Closed	-$4.86M	–	1945
2025 Q4	$4.86M	Buy	+39,864	New	+$4.57M	0.04%	336

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Vident Advisory's XBI Position: Q1 2026 in Review

Vident Advisory sold out of State Street SPDR S&P Biotech ETF (XBI) in Q1 2026, closing a stake of 39,864 shares — an estimated $4.86M sold.

Vident Advisory first reported a position in XBI in Q4 2025 and held it in 1 quarter. The position peaked at $4.86M in Q4 2025. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Vident Advisory reported no remaining State Street SPDR S&P Biotech ETF position as of Q1 2026 after selling out during the quarter.
Vident Advisory sold 39,864 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $4.86M.
Vident Advisory first reported a position in State Street SPDR S&P Biotech ETF in Q4 2025 and held it in 1 quarter.
Vident Advisory's State Street SPDR S&P Biotech ETF position peaked at $4.86M in Q4 2025.
813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Vident Advisory's 13F filing for Q1 2026, filed 15 May 2026.